Traditional immunotherapies and vaccines often rely on passive diffusion, hoping that antigens or antibodies will randomly encounter the right immune cells. This passive approach can limit the speed and potency of the resulting immune response. To overcome this limitation, a powerful strategy has emerged: using engineered molecular bridges to actively deliver antigens directly to antigen-presenting cells (APCs) or to precisely recruit innate effector cells to destroy targets. By physically linking a target to a specific immune receptor, these therapies bypass passive diffusion, force efficient cellular internalization, and trigger robust, coordinated immune responses.
Directing Antigens to Antigen-Presenting Cells
Dendritic cells and other APCs are the gatekeepers of adaptive immunity, responsible for processing antigens and presenting them to T cells. To maximize this process, researchers design vaccines that target specific surface receptors on these cells, ensuring direct delivery and providing an intrinsic activation signal.
For instance, fusing a viral protein domain to a monoclonal antibody that targets the CD40 receptor ensures the direct delivery of the antigen to the cells responsible for initiating immune responses. Romain Marlin et al. demonstrated this mechanism in Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques, showing that targeting the SARS-CoV-2 receptor-binding domain to CD40 significantly boosted neutralizing antibodies without requiring an adjuvant. Similarly, Yadira Pastor et al. utilized CD40-targeted delivery in A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease to deliver antigens directly to APCs, eliciting robust protection and sterilizing immunity against the Nipah virus.
Other surface receptors offer similar pathways for forced internalization. Gérard Zurawski et al. showed in Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques that directing low-antigenicity HIV proteins to the LOX-1 receptor on dendritic cells triggers strong humoral and cellular responses in non-human primates. Rather than relying on genetic fusions alone, the architecture can also capture circulating threats directly. Xiaohong Chen et al. developed a bispecific antibody platform in Engineered virus-hunter vaccine overcomes HBV immune tolerance that physically bridges circulating viral particles to dendritic cell receptors, successfully overcoming deep immune tolerance in chronic hepatitis B models.
This receptor-mediated internalization can also be achieved via antibody-bound complexes or cellular vesicles. Xu Daozhen et al. demonstrated in Correction: A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients that antigen-antibody complexes can target Fc receptors on APCs to force viral antigen processing and trigger T-cell activation. Alternatively, Ye Yao et al. showed in Dendritic Cells Pulsed with Leukemia Cell-Derived Exosomes More Efficiently Induce Antileukemic Immunities that incubating dendritic cells directly with isolated tumor vesicles ensures the cargo is processed and presented in a highly immunogenic context. Once delivered, the activation of these cells can be further amplified by incorporating immune-enhancing factors; for example, Lingxue Yu et al. demonstrated in Construction and in vitro evaluation of a recombinant live attenuated PRRSV expressing GM-CSF that engineering a viral vector to express GM-CSF directly promotes the expression of MHC molecules and co-stimulatory markers on dendritic cells.
Engaging Innate Immunity via Fc Effector Functions
Beyond delivering antigens to initiate an adaptive response, targeted molecular bridges can also recruit the host's innate immune system to destroy existing infected or malignant cells. This is primarily achieved through the Fc (fragment crystallizable) region of antibodies, which acts as a beacon for innate effector cells like natural killer (NK) cells, macrophages, and monocytes.
When an antibody binds to a target cell, its exposed Fc domain engages specific Fc receptors on innate cells, triggering mechanisms like Antibody-Dependent Cellular Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Wen Jiang et al. demonstrated this dual action in Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage, where the therapeutic antibody not only physically blocked the virus but also recruited macrophages and NK cells to eliminate infected cells. The clinical importance of these mechanisms is underscored by Scott D. Neidich et al. in Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk, which revealed that vaccine-elicited antibodies triggering ADCP and recruiting specific Fc receptors were strongly associated with reduced infection risk, proving more predictive of protection than simple antibody binding levels.
Furthermore, these interactions can drive long-term functional changes in innate populations. Helen R. Wagstaffe et al. showed in Durable natural killer cell responses after heterologous two-dose Ebola vaccination that vaccine-induced antibodies arm NK cells via Fc receptor engagement, enabling sustained phenotypic activation and enhanced targeted functional responses like degranulation. In oncology, these Fc-dependent mechanisms can be directed against regulatory cells to dismantle immunosuppression. In An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models, Xin Chen et al. established that an anti-TIGIT antibody requires its Fc effector function to drive ADCC and trogocytosis against immunosuppressive regulatory T cells, thereby enhancing overall anti-tumor efficacy.
Multi-Pathway Recruitment via Bispecific Engagers
The ultimate realization of this targeted approach involves combining multiple engagement strategies into a single therapeutic architecture. Bispecific "cell engagers" are engineered to simultaneously bind a specific tumor or viral antigen and an activating receptor on an immune cell, while retaining an active Fc backbone to recruit additional clearance pathways.
A prime example of this multi-pathway recruitment is the CYT-303 FLEX-NK antibody engager. As detailed by Vishal Khairnar et al. in 1320 Non-clinical characterization of CYT-303 FLEX-NK™ engager antibody supports clinical evaluation, this bispecific molecule bridges NK cells directly to liver cancer cells. Crucially, by utilizing a human IgG1 backbone, the architecture simultaneously recruits macrophages via ADCP and activates the complement system to induce Complement-Dependent Cytotoxicity (CDC).
Antonio Arulanandam et al. further characterized this mechanism in Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3, explaining that the IgG1 Fc domain broadens the therapeutic attack beyond direct NK cell killing by creating a redundant, multi-pathway anti-tumor response. By physically orchestrating these multiple arms of the immune system at once, these engineered molecules ensure highly efficient and reliable target destruction.
Key Foundational Work
Construction and in vitro evaluation of a recombinant live attenuated PRRSV expressing GM-CSF (2014) — contributed 2 concept elements to this direction.
Correction: A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients (2008) — contributed 1 concept elements to this direction.
Dendritic Cells Pulsed with Leukemia Cell-Derived Exosomes More Efficiently Induce Antileukemic Immunities (2014) — contributed 1 concept elements to this direction.